Latest News

Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims

Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims

Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Informatio...

Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, In

Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-m...

Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid

CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Po...

CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potenti

Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sul...

Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate)

European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to L...

European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucent

Teva Reports Second Quarter 2022 Financial Results

Teva Reports Second Quarter 2022 Financial Results

Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims

Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims

Teva Announces Appointment of New Global R&D and Chief Medical Officer

Teva Announces Appointment of New Global R&D and Chief Medical Officer

Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 2...

Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 20

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezu...

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)

Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Pr...

New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Present

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache So...

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society

Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Part...

Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner t

Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims

Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric As...

Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Associa

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Associatio...

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Ann

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalat...

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation P

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potentia...

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust...

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targ

Teva Reports First Quarter 2022 Financial Results

Teva Reports First Quarter 2022 Financial Results

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, ...

Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine)...

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tabl

Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims

Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims

Teva Announces Donations of Essential Medicines in Support of Ukrainian Refugees

Teva Announces Donations of Essential Medicines in Support of Ukrainian Refugees

Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.

Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.

COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis

COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis

Teva Reports Fourth Quarter and Full Year 2021 Financial Results

Teva Reports Fourth Quarter and Full Year 2021 Financial Results

Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims

Research Finds COVID Pandemic Worsened Health Equity Gap

Research Finds COVID Pandemic Worsened Health Equity Gap

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Fina

Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference

Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference